Charge Detection Mass Spectrometry

Unprecedented direct measurement for the characterization of mega-mass biomolecules

For those in scientific research, characterizing massive molecules with conventional methods can be misleading and fundamentally limiting when it comes to understanding biology and disease mechanisms. Meanwhile, those in pharmaceutical upstream process development working with new modalities are often forced to rely on tedious, expensive trial-and-error approaches to characterizing large biomolecules.

Charge detection mass spectrometry (CDMS) has the potential to address the limitations of conventional mass spectrometry in resolving native intact mega-mass complexes. With CDMS Technology, we have demonstrated precise, accurate, and high-throughput direct mass measurement and characterization of mega-mass modalities, including genetic medicines, biotherapeutics, vaccines, and protein complexes, and determination of the molecular weight, purity, and heterogeneity of biomolecules in the megadalton range and beyond, all from a benchtop device.

Want to find out more? Explore the breakthrough work of Waters scientists and collaborators in the resource section.

Click below to join our mailing list and get the latest updates on CDMS news & events.